25
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  • Upload
    illias

  • View
    83

  • Download
    0

Embed Size (px)

DESCRIPTION

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer. Presented By Boris Winterhoff at 2014 ASCO Annual Meeting. Disclosure. Presented By Boris Winterhoff at 2014 ASCO Annual Meeting. Slide 3. - PowerPoint PPT Presentation

Citation preview

Page 1: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 2: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Disclosure

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 3: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 3

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 4: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

ICON7/AGO-OVAR 11

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 5: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

ICON7/AGO-OVAR 11 <br />PFS and OS

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 6: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

ICON7/AGO-OVAR 11 <br />PFS and OS<br />High risk group suboptimal stage III and stage IV

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 7: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Molecular Classification of HGS Ovarian Cancer

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 8: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 8

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 9: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 9

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 10: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 10

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 11: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 11

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 12: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 12

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 13: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Overall (n=359)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 14: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />High risk for progression (n=119)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 15: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype (n=96)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 16: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype (n=68)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 17: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Differentiated Subtype (n=73)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 18: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Immunoreactive Subtype (n=122)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 19: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Slide 19

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 20: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype HGS (n=63)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 21: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype HGS (n=43)

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 22: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Summary

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 23: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Conclusion

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 24: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Acknowledgements

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Page 25: Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Summary

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting